KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Asset Writedowns and Impairment (2022 - 2025)

Nektar Therapeutics (NKTR) has 4 years of Asset Writedowns and Impairment data on record, last reported at $8.3 million in Q2 2024.

  • For Q2 2024, Asset Writedowns and Impairment rose 17.31% year-over-year to $8.3 million; the TTM value through Mar 2025 reached $8.3 million, down 47.86%, while the annual FY2024 figure was $8.3 million, 76.42% down from the prior year.
  • Asset Writedowns and Impairment reached $8.3 million in Q2 2024 per NKTR's latest filing, up from -$1.3 million in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $57.3 million in Q2 2022 and bottomed at -$1.3 million in Q4 2023.
  • Average Asset Writedowns and Impairment over 3 years is $12.7 million, with a median of $7.8 million recorded in 2022.
  • The widest YoY moves for Asset Writedowns and Impairment: up 747.75% in 2023, down 117.96% in 2023.
  • A 3-year view of Asset Writedowns and Impairment shows it stood at $7.2 million in 2022, then tumbled by 117.96% to -$1.3 million in 2023, then surged by 740.69% to $8.3 million in 2024.
  • Per Business Quant database, its latest 3 readings for Asset Writedowns and Impairment were $8.3 million in Q2 2024, -$1.3 million in Q4 2023, and $10.2 million in Q3 2023.